For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback